ASO Author Reflections: Objective Response Rate after Short Duration (< 9 Weeks) Is Not Inferior to Moderate (9–27 Weeks) or Long Duration (> 27 Weeks) of Neoadjuvant Endocrine Therapy (NET)—An NCDB Analysis
- 24 July 2021
- journal article
- editorial
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 28 (13) , 8663-8664
Abstract
No abstract availableThis publication has 5 references indexed in Scilit:
- Effectiveness of a Short Duration of Neoadjuvant Endocrine Therapy in Patients with HR+ Breast Cancer—An NCDB Analysis (2004–2016)Annals of Surgical Oncology, 2021
- Changes in Recurrence Score by neoadjuvant endocrine therapy of breast cancer and their prognostic implicationESMO Open, 2019
- Neoadjuvant Endocrine Therapy for Estrogen Receptor–Positive Breast CancerJAMA Oncology, 2016
- Trends in Neoadjuvant Endocrine Therapy Use and Impact on Rates of Breast Conservation in Hormone Receptor-Positive Breast Cancer: A National Cancer Data Base StudyAnnals of Surgical Oncology, 2016
- Optimum duration of neoadjuvant letrozole to permit breast conserving surgeryBreast Cancer Research and Treatment, 2014